image

R&D Platform

A novel approach anchored in a deep understanding of patient anti-tumor immune responses

More +

image

THERAPEUTICS

Atreca is creating a new class of immuno-oncology agents.

More +

Technology

Atreca’s proprietary Immune Response Capture™ (IRC™) technology provides unbiased and virtually error-free antibody and T cell receptor (TCR) sequences from adaptive immune responses in humans and other species.  IRC™ generates immune repertoire information with key advantages:

  • Natively paired substituent chains.  IRC™ tracks the co-expression of genes from the same single cell, so truly native antibodies and TCRs are recovered.   Only by pairing the (antibody) heavy and light and (TCR) alpha and beta chains expressed in the same single cells can both accurate quantitation and consistent function be achieved.
  • Full immunoglobulin sequences.  IRC™ generates sequence information from the beginning of signal sequences through constant regions of immunoglobulins, delivering full-length variable domains (including all complementarity-determining and framework regions) and isotype information.
  • Error-corrected sequences.  IRC™ corrects for sequence errors introduced at all steps of a single-cell analysis process (reverse transcription, PCR amplification, and next-generation sequencing) so that all antibodies and TCRs identified in a repertoire are ready for expression.  Without such correction, process errors cannot be distinguished from true biological variation, rendering both quantitation of immune responses and function of expressed proteins impossible.
  • Unbiased output.  IRC™ corrects for biases from PCR amplification and other sources (such as the use of degenerate primers), so the output delivers true clonal frequencies in an immune response.

Atreca_IRC_update

The exceptional data quality delivered by Atreca’s IRC™ technology enables accurate quantitation of immune responses, including accurate measurement of clonal frequencies, tracking sequence and clonal evolution over time, and identification of convergent evolution across multiple individuals.

Any sequence delivered by Atreca’s IRC™ technology is ready for immediate gene synthesis, expression, and testing, without the need for re-sequencing or re-cloning.  The resulting functional proteins can be used directly in a wide variety of downstream applications, including identifying the targets of immune responses.  Applied to human disease, Immune Repertoire Capture™ technology is an engine for the discovery and development of therapeutics, vaccines, and diagnostics in cancer, infectious disease, and autoimmune disease.

image

R&D Platform

A novel approach anchored in a deep understanding of patient anti-tumor immune responses

More +

image

THERAPEUTICS

Atreca is creating a new class of immuno-oncology agents.

More +